Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA

Kura Oncology

Kura Oncology is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker KURA. Primary therapeutic focus areas include Acute Myeloid Leukemia, Relapsed and/or refractory Acute Myeloid Leukem

12730 High Bluff Dr, Suite 400, San Diego, California 92130, US HQ
2014 Founded
313 Employees
Public company Type
KURA · NYSE Ticker
Company details
Status
Public
HQ
12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
Founded
2014
Employees
313
Programs
25
Drugs
14
Patents
132
Clinical program

Dexamethasone

Phase 2 · small molecule · Lymphoblastic Leukemia

Dexamethasone for Lymphoblastic Leukemia is a Phase 2 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).

← All Kura Oncology projects Phase 2 small molecule active

Internal code IRB-68271

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Kura Oncology
Phase
Phase 2
Modality
small_molecule
Indication
Lymphoblastic Leukemia
Status
active
Trials
1